InSite Vision, working off its eye drop platform with polymer-suspended drug delivery, is planning to submit an NDA in 2015 for its treatment for blepharitis, an eyelid inflammation disease for which there is currently no FDA-approved treatment.
Researchers at the University of Georgia have developed a new formulation of the chemotherapy drug cisplatin that targets mitochondrial DNA, and is delivered via a polymeric nanoparticle 1,000 times smaller than the width of human hair.
Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.
The U.S. National Institutes of Health granted Sorrento Therapeutics $2.6 million to develop antibacterial immunotherapies.
A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.
A novel intravaginal ring to prevent HIV showed promise in pig-tailed macaque monkeys, demonstrating the benefits of sustained and controlled topical drug delivery over oral intake.
BioDelivery Sciences has completed enrollment of it Phase III study clonidine topical gel for the treatment of painful diabetic neuropathy (PDN).
Self-propelled drug delivery robots offer the type of precise targeting and maneuverability needed to make better treatments. And U.S. engineers have designed a type of robot that's powered by real muscle cells, offering controlled movement via electrical pulses, an innovation that could find its way into the drug delivery arena down the road.
Researchers are attempting to develop methods of sneaking drugs past bacteria's external defense system by delivering therapies via molecules that bacteria secrete to find and obtain iron.
Bristol-Meyers Squibb recalled six lots of 5 mg single-use vials of Coumadin for Injection due to the presence of particulate matter, but the FDA said the issue does not affect the more prevalent oral formulation of the popular blood thinner.
Researchers in Boston have developed new drug-delivering nanoparticles that could target and kill bone cancer cells by homing in on calcium. Besides showing in mouse models to slow myeloma growth and prolonging survival, the treatment also enhanced bone strength and volume.
MicroLin Bio, a developer of microRNA treatments for cancer, is expected to price its $30 million IPO on the Nasdaq this week. Delays and share dilution have taken some of the shine off the event, but investors enthiusiam will ultimately hinge on the fate of its proprietary nanoparticle delivery technology.
Transdermal microneedle patch maker Zosano filed for a $65 million IPO on the Nasdaq with the U.S. Securities and Exchange Commission. The share price and number of shares to be offered under the ticker symbol ZSAN were not disclosed.
A drug-eluting patch developed by researchers at Nanyang Technological University in Singapore could offer a solution for patients with overgrown scar tissue.
The FDA on June 24 issued three final guidances and a draft guidance for industry to clarify the use of nanotechnology in FDA-regulated products, a decision that will affect the drug delivery arena as it becomes more dependent on nano-engineerin
Harvard University researchers have developed a system for releasing high doses of drugs in short bursts using ultrasound and self-healing hydrogel. Future therapy could therefore be highly customized and locally delivered at specific times, as opposed to the dominant sustained release paradigm.
InVivo Therapeutics announced June 19 that it is terminating its preclinical hydrogel drug delivery program as the company focuses on its investigational devices for spinal cord injury, the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells.
Intersect ENT, the maker of a drug-delivering implant designed to treat sinusitus, is joining a spate of biotech companies that have recently jumped into the IPO pool. Intersect, filing with the SEC on Monday, hopes to raise up to $80 million in the offering.
A new type of drug delivery vehicle from the University of Pennsylvania is made up of several membranes layered on each other to protect the drug at its core or possibly deliver a few different drugs over time.
Researchers at The Ohio State University have found that to treat brain cancer and other solid tumors, a low dose of the proteasome inhibitor bortezomib improves oncolytic viruses' ability to kill cancer cells.